Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Myxoid liposarcoma with negative features on bone scan and [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography.

Sakamoto A, Fukutoku Y, Matsumoto Y, Harimaya K, Oda Y, Iwamoto Y.

World J Surg Oncol. 2012 Oct 9;10:214. doi: 10.1186/1477-7819-10-214.

2.

Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging.

Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH.

Cancer. 2007 Oct 15;110(8):1815-22.

3.

Multi-level total en bloc spondylectomy for solitary lumbar metastasis of myxoid liposarcoma.

Kato S, Kawahara N, Murakami H, Demura S, Shirai T, Tsuchiya H, Tomita K.

Orthopedics. 2010 Jun 9;33(6):446. doi: 10.3928/01477447-20100429-33.

PMID:
20806757
4.

High 2-deoxy-2[F-18]fluoro-D-glucose uptake on positron emission tomography in hibernoma originally thought to be myxoid liposarcoma.

Lin D, Jacobs M, Percy T, Dowdy Y, Mantil J.

Mol Imaging Biol. 2005 May-Jun;7(3):201-2. Epub 2005 Apr 22.

PMID:
15912423
5.

Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma.

Conill C, Setoain X, Colomo L, Palacín A, Combalia-Aleu A, Pomés J, Marruecos J, Vargas M, Maurel J.

J Magn Reson Imaging. 2008 Mar;27(3):625-8. doi: 10.1002/jmri.21298.

PMID:
18307201
6.

Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.

Gayed I, Vu T, Johnson M, Macapinlac H, Podoloff D.

Mol Imaging Biol. 2003 Jan-Feb;5(1):26-31.

PMID:
14499159
7.

(18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.

Asabella AN, Cimmino A, Altini C, Notaristefano A, Rubini G.

Hell J Nucl Med. 2011 Sep-Dec;14(3):311-2.

PMID:
22087457
8.

Round cell liposarcoma arising in the left foot: MRI and PET findings.

Kudo H, Inaoka T, Tokuyama W, Hiruta N, Nakagawa K, Hayashi A, Terada H.

Jpn J Radiol. 2012 Dec;30(10):852-7. doi: 10.1007/s11604-012-0119-y. Epub 2012 Sep 12.

PMID:
22965582
9.

Metastatic myxoid liposarcomas: imaging and histopathologic findings.

Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA.

Skeletal Radiol. 2008 Mar;37(3):251-8. Epub 2007 Dec 21.

PMID:
18097662
10.

Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.

Ak I, Sivrikoz MC, Entok E, Vardareli E.

Eur J Cardiothorac Surg. 2010 Apr;37(4):792-6. doi: 10.1016/j.ejcts.2009.11.011. Epub 2009 Dec 16.

PMID:
20015657
11.

Neurological deficit from metastatic low grade liposarcoma.

Taweevisit M, Thanakit V.

J Med Assoc Thai. 2005 Apr;88(4):538-40.

PMID:
16146262
12.

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA.

Breast Cancer Res Treat. 2007 Sep;105(1):87-94. Epub 2007 Feb 1.

PMID:
17268819
13.

[Case of renal cell carcinoma with intertrabecular vertebral metastases detected f-18 fluorodeoxyglucose positron emission tomography and MRI].

Yoneyama S, Yumura Y, Koizumi M, Hanai T, Ishida H, Hattori Y, Teranishi J, Miyoshi Y, Kondo K, Noguchi K.

Hinyokika Kiyo. 2014 Jan;60(1):29-32. Japanese.

14.

11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.

Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, Farsad M, Castellucci P, Ambrosini V, Montini GC, Al-Nahhas A, Franchi R, Fanti S.

World J Surg Oncol. 2007 Jun 20;5:68.

15.

Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.

Ozcan Kara P, Kara T, Kara Gedik G, Sari O, Sahin O.

Rev Esp Med Nucl. 2011 Mar-Apr;30(2):94-6. doi: 10.1016/j.remn.2010.10.008. Epub 2011 Feb 20.

16.

¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V.

Clin Exp Med. 2015 Feb;15(1):1-18. doi: 10.1007/s10238-014-0308-3. Epub 2014 Sep 14. Review.

PMID:
25218739
17.

A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels.

Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M, Jousse F, Eckelman WC, Kranda K, Neumann RD, Carrasquillo JA.

Ann Surg Oncol. 2001 Dec;8(10):779-86.

PMID:
11776491
18.

Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.

Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE.

Dis Colon Rectum. 2000 Jun;43(6):759-67; discussion 767-70.

PMID:
10859074
19.

Unusual skeletal metastases from myxoid liposarcoma only detectable by MR imaging.

Ishii T, Ueda T, Myoui A, Tamai N, Hosono N, Yoshikawa H.

Eur Radiol. 2003 Dec;13 Suppl 4:L185-91.

PMID:
15018186
20.

Positron emission tomography and bone metastases.

Fogelman I, Cook G, Israel O, Van der Wall H.

Semin Nucl Med. 2005 Apr;35(2):135-42. Review.

PMID:
15765376

Supplemental Content

Support Center